In a significant development on Wednesday, the Enforcement Directorate (ED) carried out a series of raids at eight locations across Mumbai and other parts of India, targeting an alleged bank fraud involving Rs 220 crore. The ED's investigation centers around Sharon Bio-Medicine, a pharmaceutical company, and its associates who are accused of orchestrating a large-scale bank fraud. Sources close to the investigation revealed that during these operations, the ED seized assets valued at Rs 14.53 crore, including bank funds, demat accounts, and various incriminating documents.
CBI Investigation Led to ED Probe
The origins of this case trace back to an FIR filed by the Central Bureau of Investigation (CBI), whose probe has been instrumental in uncovering the alleged financial misconduct at Sharon Bio-Medicine. The CBI investigation initially implicated several individuals, including Mohan Prasad Kala, Savita Satish Gowda, and Lalit Shambu Misra, among others. According to the CBI, these individuals were involved in the submission of forged documents to various banks, which allowed the company to secure substantial credit facilities. The ED’s investigation, built on the CBI’s findings, delves into the money laundering aspects of this alleged fraud, following a trail of financial misappropriation aimed at creating personal assets through questionable financial maneuvers.
Fabricated Documentation and Fictitious Contracts Alleged
As per the ED, Sharon Bio-Medicine, a company specializing in the production of active pharmaceutical ingredients, allegedly presented banks with fake contracts and forged paperwork to obtain credit. Once these loans were secured, ED officials suspect that the funds were diverted away from legitimate business activities and instead used to create personal assets. The agency seized or froze various assets valued at Rs 14.53 crore during the raids, which included movable assets such as bank balances and demat accounts.
Shell Companies Used to Inflate Turnover and Siphon Funds
Investigators believe that Sharon Bio-Medicine set up a web of shell companies, enabling it to inflate turnover figures artificially through fictitious sales and purchases. These inflated figures reportedly provided grounds for the company to enhance its credit facilities with banks, thereby securing larger loans. ED sources claim that once the loans were approved, the funds were routed through multiple shell companies, which were registered under the names of SBML employees and relatives of key personnel. This complex network allowed Sharon Bio-Medicine to redirect funds into personal assets while concealing the true nature of these financial transactions.
ED Investigation Ongoing
The ED’s investigation remains ongoing as officials examine additional digital evidence, property records, and financial documentation recovered during the raids. This high-profile case underscores the ED's crackdown on financial misconduct within the pharmaceutical sector and its commitment to holding companies accountable for defrauding public institutions.
Share
Tweet
